BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 28559413)

  • 1. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple negative breast cancer: special histological types and emerging therapeutic methods.
    Cao L; Niu Y
    Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative breast cancer: molecular subtypes and targeted therapy.
    Hirshfield KM; Ganesan S
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):34-40. PubMed ID: 24346128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
    Zuo T; Wilson P; Cicek AF; Harigopal M
    Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
    Diaz LK; Cryns VL; Symmans WF; Sneige N
    Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple negative breast cancer: the kiss of death.
    Jitariu AA; Cîmpean AM; Ribatti D; Raica M
    Oncotarget; 2017 Jul; 8(28):46652-46662. PubMed ID: 28445140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
    Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
    Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
    Peng Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of triple-negative breast cancer.
    Kumar P; Aggarwal R
    Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology of triple negative breast cancer.
    Borri F; Granaglia A
    Semin Cancer Biol; 2021 Jul; 72():136-145. PubMed ID: 32544511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the difference between triple-negative and basal breast cancers?
    Seal MD; Chia SK
    Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.